BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

24 related articles for article (PubMed ID: 32318943)

  • 1. Impact of Removal of Lymph Nodes on Survival in Stage I-III Gastric Signet-Ring Cell Cancer: The More, the Better?
    Jiang Y; Shao X; Li W; Hu H; Lu Y; Li Y; Tian Y
    Ann Surg Oncol; 2024 Feb; 31(2):783-791. PubMed ID: 37991582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exceeding 30 ELNs is strongly recommended for pT3-4N0 patients with gastric cancer: A multicenter study of survival, recurrence, and prediction model.
    Zhao L; Han W; Yang X; Zhao D; Niu P; Gao X; Wu Z; Zhang X; Li Z; Ji G; Chen Y
    Cancer Sci; 2021 Aug; 112(8):3266-3277. PubMed ID: 34080256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Significance of examined lymph nodes number and metastatic lymph nodes ratio in overall survival and adjuvant treatment decision in resected laryngeal carcinoma.
    Zhu X; Zhao M; Zhou L; Zhang M; Cao P; Tao L
    Cancer Med; 2020 May; 9(9):3006-3014. PubMed ID: 32112627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extensive lymphadenectomy may improve survival in node negative oesophageal cancer.
    Khoma O; Paredes SR; Park JS; Kennedy CW; Falk GL
    Sci Rep; 2024 Feb; 14(1):2711. PubMed ID: 38302610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic factors and the necessity of chemotherapy for stage II gastric cancer: a model based on multicenter retrospective study.
    Fang J; Zhang F; Lu J; Deng Z; Li X; Chen X; Huang C; Chen Y; Lian L; Peng J; Chen S
    Discov Oncol; 2023 May; 14(1):58. PubMed ID: 37154867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Four Lymph Node Staging Systems in Gastric Adenocarcinoma after Neoadjuvant Therapy - A Population-Based Study.
    Lai H; Zheng J; Li Y
    Front Surg; 2022; 9():918198. PubMed ID: 35756471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lymph Node Involvement in Advanced Gastric Cancer in the Era of Multimodal Treatment-Oncological and Surgical Perspective.
    Pelc Z; Skórzewska M; Rawicz-Pruszyński K; Polkowski WP
    Cancers (Basel); 2021 May; 13(10):. PubMed ID: 34065596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic Value of the Number of Lymph Nodes Examined in Patients with Node-Negative Gastric Cancer.
    Yang ZL; Zhu MH; Shi Q; Lu FM; Wang CX
    J Gastrointest Surg; 2019 Mar; 23(3):460-467. PubMed ID: 30225793
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Lymph Nodes Examined on Survival in ypN0 Gastric Cancer Patients: a Population-Based Study.
    MingHua Z; KeCheng Z; ZhenYu C; Lin C; ChunXi W; ZeLong Y
    J Gastrointest Surg; 2021 Apr; 25(4):919-925. PubMed ID: 32318943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A nomogram model based on the number of examined lymph nodes-related signature to predict prognosis and guide clinical therapy in gastric cancer.
    Li H; Lin D; Yu Z; Li H; Zhao S; Hainisayimu T; Liu L; Wang K
    Front Immunol; 2022; 13():947802. PubMed ID: 36405735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of examined lymph node count on staging and long-term survival of patients with node-negative stage III gastric cancer: a retrospective study using a Chinese multi-institutional registry with Surveillance, Epidemiology, and End Results (SEER) data validation.
    Zhang N; Bai H; Deng J; Wang W; Sun Z; Wang Z; Xu H; Zhou Z; Liang H
    Ann Transl Med; 2020 Sep; 8(17):1075. PubMed ID: 33145294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The minimum number of examined lymph nodes was 24 for optimal survival of pathological T2-4 gastric cancer: a multi-center, hospital-based study covering 20 years of data.
    Zhao L; Zhang F; Jiao F; Zhou X; Niu P; Han X; Wang W; Luan X; He M; Guan Q; Li Y; Zhao D; Gao J; Chen Y
    BMC Cancer; 2023 Sep; 23(1):892. PubMed ID: 37735628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Total Lymph Node Yield Is Associated with Prolonged Survival after Neoadjuvant Chemotherapy in ypN0 Gastric Cancer Patients.
    Li W; Shao X; Ma F; Wang B; Xue L; Hu H; Kang W; Xiong J; Tian Y
    Oncol Res Treat; 2023; 46(7-8):287-295. PubMed ID: 37302386
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.